The Topic of Neurological Care for Transgender Patients - Part 2

Dr. Gregg Day and Dr. Kathryn T. Hall discuss the complexities of the placebo effect, its variability among patients, and the genetic factors that influence responses to placebo treatments. 

In part two of this three-part series, Dr. Justin Abbatemarco and Dr. Ahmad Nehme discuss the underlying pathophysiology and how to diagnose primary angiitis of the CNS in clinical practice. Show reference: https://www.neurology.org/doi/abs/10.1212/WNL.0000000000209548 

In part one of this three-part series, Dr. Justin Abbatemarco and Dr. Ahmad Nehme discuss how cerebral amyloid angiopathy and CAA-RI present in clinical practice and how to make a diagnosis. Show reference: https://www.neurology.org/doi/abs/10.1212/WNL.0000000000209548 

Dr. Stacey Clardy discusses vitamin D in this lab minute.

Dr. Halley Alexander discusses the Neurology Today article, "Could Reducing Environmental Toxins Help Mitigate the Risk for Parkinson’s Disease? Where the Evidence Is Leading" by Gina Shaw, available in the November 7th issue of Neurology Today or at neurologytoday.com. Show reference: https://journals.lww.com/neurotodayonline/pages/articleviewer.aspx?year=2024&issue=11070&article=00001&type=Fulltext

In the final part of this three-part series, Dr. Justin Abbatemarco and Dr. Jennifer L. Orthmann Murphy highlight important indicators for when to suspect hereditary spastic paraplegia, as well as guidelines for testing and interpreting results.  Show references: https://www.neurology.org/doi/10.1212/NXG.0000000000200192  https://cshperspectives.cshlp.org/content/early/2024/08/10/cshperspect.a041457

In part two of this three-part series, Dr. Justin Abbatemarco and Dr. Jennifer L. Orthmann Murphy discuss practical approaches to genetic adrenoleukodystrophy. Show references: https://www.neurology.org/doi/10.1212/NXG.0000000000200192  

In the first part of this three-part series, Dr. Justin Abbatemarco and Dr. Jennifer L. Orthmann Murphy discuss red flag symptoms that suggest the need for genetic testing in patients with white matter disease. Show references: https://www.neurology.org/doi/10.1212/NXG.0000000000200192 https://cshperspectives.cshlp.org/content/early/2024/08/10/cshperspect.a041457

Dr. Rae Bacharach discusses the Neurology Today article, “Early Treatment Cuts Relapse Risk in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease,” by Gina Shaw, available in the latest issue of Neurology Today or at neurologytoday.com.  Show reference: https://journals.lww.com/neurotodayonline/pages/default.aspx https://jamanetwork.com/journals/jamaneurology/article-abstract/2822964 

In the final part of this three-part series, Drs. Tesha Monteith, Messoud Ashina, and Andrea Cipriani discuss what you need to know about analyzing network meta-analysis. Show reference: https://www.bmj.com/content/386/bmj-2024-080107